The latest price target for ProQR Therapeutics (NASDAQ:PRQR) was reported by HC Wainwright & Co. on November 8, 2024. The analyst firm set a price target for $10.00 expecting PRQR to rise to within 12 months (a possible 177.01% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for ProQR Therapeutics (NASDAQ:PRQR) was provided by HC Wainwright & Co., and ProQR Therapeutics maintained their buy rating.

The last upgrade for ProQR Therapeutics NV happened on October 29, 2024 when Raymond James raised their price target to $14. Raymond James previously had an outperform for ProQR Therapeutics NV.

The last downgrade for ProQR Therapeutics NV happened on August 12, 2022 when Chardan Capital changed their price target from N/A to N/A for ProQR Therapeutics NV.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on November 8, 2024 so you should expect the next rating to be made available sometime around November 8, 2025.

While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a maintained with a price target of $5.00 to $10.00. The current price ProQR Therapeutics (PRQR) is trading at is $3.61, which is out of the analyst’s predicted range.